Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 3, 2008 - Issue 4
Submit an article Journal homepage
28
Views
0
CrossRef citations to date
0
Altmetric
Review

Phosphatonins: new hormones that control phosphorus homeostasis

Gemma Marcucci Department of Internal Medicine and # De Gene Spin-off, University of Florence, Medical School, Florence, Italy
,
Laura Masi Department of Internal Medicine and # De Gene Spin-off, University of Florence, Medical School, Florence, Italy
&
Maria Luisa Brandi Department of Internal Medicine, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy. [email protected]
Pages 513-526 | Published online: 10 Jan 2014

References

  • Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int.65, 1–14 (2004).
  • Knochel JP, Barcenas C, Cotton JR et al. Hypophosphatemia and rhabdomyolysis. Trans. Assoc. Am. Physicians91, 156–168 (1978).
  • Berndt T, Knox F. Renal regulation of phosphate excretion. In: The Kidney: Physiology and Pathophysiology. Seldin D, Giebisch G (Eds). Raven Press, NY, USA 2511–2532 (1992).
  • Steele TH, Underwood JL. Renal response to phosphorus deprivation in the isolated rat kidney. Kidney Int.13, 124–128 (1978).
  • Sommer S, Berndt T, Craig T et al. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J. Steroid Biochem. Mol. Biol.103, 497–503 (2007).
  • Miyamoto K, Ito M, Tatsumi S et al. New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am. J. Nephrol.27, 503–515 (2007)
  • Forster IC, Virkki L, Bossi E et al. Electrogenic kinetics of a mammalian intestinal type IIb Na+/P(i) cotransporter. J. Membr. Biol.212, 177–190 (2006).
  • Hernando N, Biber J, Forster I et al. Recent advances in renal phosphate transport. Ther. Apher. Dial.9, 323–327 (2005).
  • Juppener H. Novel regulators of phosphate homeostasis and bone metabolism. Ther. Apher. Dial. (Suppl.1), S3–S22 (2007).
  • Segawa H, Kaneko I, Yamanaka S et al. Intestinal Na–P(i) cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice. Am. J. Physiol. Renal Physiol.287, F39–F47 (2004).
  • Barthel TK, Mathern DR, Whitfield GK et al. 1,25-dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J. Steroid Biochem. Mol. Biol.103, 381–388 (2007).
  • Murer H, Hernando N, Forster L et al. Molecular mechanisms in proximal tubular and small intestinal phosphate reabsorption (plenary lecture). Mol. Membr. Biol.18, 3–11 (2001).
  • Schiavi SC, Moe OW. Phosphatonins: a new class of phosphate-regulating proteins. Curr. Opin. Nephrol. Hypertens.11, 423–430 (2002).
  • Brown AJ, Koch MJ, Coyne DW. Oral feeding acutely down-regulates serum PTH in hemodialysis patients. Nephron Clin. Pract.103, c106–c113 (2006).
  • Martin DR, Ritter CS, Slatopolsky E et al. Acute regulation of parathyroid hormone by dietary phosphate. Am. J. Physiol. Endocrinol. Metab.289, E729–E734 (2005).
  • Landsman A, Lichtstein D, Ilani A. Distinctive features of dietary phosphate supply. J. Appl. Physiol.99, 1214–1219 (2005).
  • White KE, Larsson TE, Econs MJ. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr. Rev.27, 221–241 (2006).
  • Cai Q, Hodgson SF, Kao PC et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N. Engl. J. Med.330, 1645–1649 (1994).
  • Econs MJ, Drezner MK. Tumor-induced osteomalacia – unveiling a new hormone. N. Engl. J. Med.330, 1679–1681 (1994).
  • Kumar R. Phosphatonin – a new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia). Nephrol. Dial. Transplant.12, 11–13 (1997).
  • Berndt TJ, Schiavi S, Kumar R. ‘Phosphatonins’ and the regulation of phosphorus homeostasis. Am. J. Physiol. Renal Physiol.289, F1170–F1182 (2005).
  • Imel EA, Econs MJ. Fibroblast growth factor 23: roles in health and disease. J. Am. Soc. Nephrol.16, 2565–2575 (2005).
  • Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl Acad. Sci. USA98, 6500–6505 (2001).
  • Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res Commun.277, 494–498 (2000).
  • Goetz R, Beenken A, Ibrahimi OA et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol.27, 3417–3428 (2007).
  • Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab.291, E38–E49 (2006).
  • Sitara D, Razzaque MS, Hesse M et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol.23, 421–432 (2004).
  • Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest.113, 561–568 (2004).
  • Larsson T, Marsell R, Schipani E et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology145, 3087–3094 (2004).
  • Bai XY, Miao D, Goltzman D et al. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J. Biol. Chem.278, 9843–9849 (2003).
  • Bai X, Miao D, Li J et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology145, 5269–5279 (2004).
  • Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res.19, 429–435 (2004).
  • Miyamoto K, Ito M, Kuwahata M et al. Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther. Apher. Dial.9, 331–335 (2005).
  • Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin. Dial.20, 302–308 (2007).
  • Berndt TJ, Craig TA, McCormick DJ et al. Biological activity of FGF-23 fragments. Pflugers Arch.454, 615–623 (2007).
  • Yamashita T, Konishi M, Miyake A et al. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J. Biol. Chem.277, 28265–28270 (2002).
  • Yu X, Ibrahimi OA, Goetz R et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology146, 4647–4656 (2005).
  • Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer7, 165–197 (2000).
  • Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature444, 770–774 (2006).
  • Garringer HJ, Fisher C, Larsson TE et al. The role of mutant UDP-N-acetyl-α-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J. Clin. Endocrinol. Metab.91, 4037–4042 (2006).
  • Rowe PS. The wrickkened pathways of FGF23, MEPE and PHEX. Crit. Rev. Oral Biol. Med.15, 264–281 (2004).
  • Yu X, White KE. Fibroblast growth factor 23 and its receptors. Ther. Apher. Dial.9, 308–312 (2005).
  • Kurosu H, Yamamoto M, Clark JD et al. Suppression of aging in mice by the hormone Klotho. Science309, 1829–1833 (2005).
  • Li SA, Watanabe M, Yamada H et al. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct. Funct.29, 91–99 (2004).
  • Fukuda T, Kanomata K, Nojima J et al. FGF23 induces expression of two isoforms of NAB2, which are corepressors of Egr-1. Biochem. Biophys. Res. Commun.353, 147–151 (2007).
  • Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int.64, 2272–2279 (2003).
  • Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab.90, 1519–1524 (2005).
  • Nishida Y, Yamonaka-Okumura H, Taketani Y et al. Postprandial changes of serum fibroblast growth factor (FGF23) levels on high phosphate diet in healthy men. Presented at: Annual Meeting American Society for Bone and Mineral Research, Nashville, TN, USA, 23–27 February, 2005.
  • Perwad F, Azam N, Zhang MY et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology146, 5358–5364 (2005).
  • Berndt T, Thomas LR, Craig TA et al. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc. Natl Acad. Sci. USA104(26), 11085–11090 (2007).
  • Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol.17, 1305–1315 (2006).
  • Nishi H, Nii-Kono T, Nakanishi S et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin. Pract.101, c94–c99 (2005).
  • Perwad F, Zhang MYH, Tenenhouse HS et al. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1α-hydroxylase expression in vitro. Am. J. Physiol. Renal Physiol.293, F1577–F1583 (2007).
  • Krajisnik T, Bjorklund P, Marsell R et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells. J. Endocrinol.195, 125–131 (2007).
  • Ben Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest117, 4003–4008 (2007).
  • Feng JQ, Ward LM, Liu S et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet.38, 1230–1231 (2006).
  • Lorenz-Depiereux B, Bastepe M, Benet-Pages A et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat. Genet.38, 1248–1250 (2006).
  • Wagner CA. Novel insights into the regulation of systemic phosphate homeostasis and renal phosphate excretion. J. Nephrol.20, 130–134 (2007).
  • The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet.26, 345–348 (2000).
  • Shimada T, Muto T, Urakawa I. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology143, 3179–3182 (2002).
  • White KE, Carn G, Lorenz-Depiereux B et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int.60, 2079–2086 (2001).
  • Shimada T, Urakawa I, Yamazaki Y et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun.314, 409–414 (2004).
  • Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med.348, 1656–1663 (2003).
  • Takeuchi Y, Suzuki H, Ogura S et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J. Clin. Endocrinol. Metab.89, 3979–3982 (2004).
  • Berndt T, Craig TA, Bowe AE et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J. Clin. Invest.112, 785–794 (2003).
  • The Hyp Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat. Genet.11, 130–136 (1995).
  • Ruchon AF, Marcinkiewicz M, Siegfried G et al. Phex mRNA is localized in developing mouse osteoblasts and odontoblasts. J. Histochem. Cytochem.46, 459–468 (1998).
  • Meyer RA Jr, Tenenhouse HS, Meyer MH et al. The renal phosphate transport defect in normal mice parabiosed to X-linked hypophosphatemic mice persists after parathyroidectomy. J. Bone Miner. Res.4, 523–532 (1989).
  • Nesbitt T, Coffman TM, Griffiths R et al. Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J. Clin. Invest.89, 1453–1459 (1992).
  • Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab.87, 4957–4960 (2002).
  • Bowe AE, Finnegan R, Jan de Beur SM et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem. Biophys. Res. Commun.284, 977–981 (2001).
  • Campos M, Couture C, Hirata IY et al. Human recombinant endopeptidase PHEX has a strict S1´ specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem. J.373, 271–279 (2003).
  • Liu S, Guo R, Simpson LG et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J. Biol. Chem.278, 37419–37426 (2003)
  • Benet-Pagès A, Lorenz-Depiereux B, Zischka H et al. FGF23 is processed by proprotein convertase but not by PHEX. Bone35, 455–462 (2004).
  • Liu S, Tang W, Zhou J et al. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am. J. Physiol. Endocrinol. Metab.293, E1636–E1644 (2007).
  • Riminucci M, Collins MT, Fedarko NS et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest.112, 683–692 (2003).
  • Imel EA, Econs MJ. Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23. Pediatr. Endocrinol. Rev.4(Suppl. 4), 434–439 (2007).
  • Garringer HJ, Mortazavi SM, Esteghamat F et al. Two novel GALNT3 mutations in familial tumoral calcinosis. Am. J. Med. Genet. A143, 2390–2396 (2007).
  • Ichikawa S, Imel EA, Sorenson AH et al. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. J. Clin. Endocrinol. Metab.91, 4472–4475 (2006).
  • Ichikawa S, Guigonis V, Imel EA et al. Novel GALNT3 mutations causing hyperostosis–hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. J. Clin. Endocrinol. Metab.92, 1943–1947 (2007).
  • Topaz O, Shurman DL, Bergman R et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat. Genet.36, 579–581 (2004).
  • Chefetz I, Heller R, Galli-Tsinopoulou A et al. A novel homozigous missense mutation in FGF23 causes familial tumoral calcinosis associated with disseminated visceral calcification. Hum. Genet.118, 261–266 (2005).
  • Specktor P, Cooper JG, Indelman M et al. Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred. J. Hum. Genet.51, 487–489 (2006).
  • Ichikawa S, Imel EA, Kreiter ML et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J. Clin. Invest.117, 2684–2691 (2007).
  • Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu. Rev. Physiol.69, 341–359 (2007).
  • Frishberg Y, Ito N, Rinat C et al. Hyperostosis–hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J. Bone Miner. Res.22, 235–242 (2007).
  • Benet-Pages A, Orlik P, Strom TM et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet.14, 385–390 (2005).
  • Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF23 in CKD. Nephrol. Dial. Transplant.20, 1295–1298 (2005).
  • Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am. J. Kidney Dis.44, 250–256 (2004).
  • Gutierrez O, Isakova T, Rhee E et al.Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol.16, 2205–2215 (2005).
  • Fukagawa M, Kazama JJ. FGF23: its role in renal bone disease. Pediatr. Nephrol.21, 1802–1806 (2006).
  • Urena TP, Friedlander G, de Vernejoul MC et al. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int.73, 102–107 (2008).
  • Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int.67, 1120–1125 (2005).
  • Nakanishi S, Kazama JJ, Nii-Kono T et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int.67, 1171–1178 (2005).
  • Foley RN, Li S, Liu J et al. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J. Am. Soc. Nephrol.16, 210–218 (2005).
  • Charytan C, Coburn JW, Chonchol M et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am. J. Kidney Dis.46, 58–67 (2005).
  • Sato T, Tominaga Y, Ueki T et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am. J. Kidney Dis.44, 481–487 (2004).
  • Mirams M, Robinson BG, Mason RS et al. Bone as a source of FGF23: regulation by phosphate? Bone35, 1192–1199 (2004).
  • Yamashita H, Yamashita T, Miyamoto M et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur. J. Endocrinol.151, 55–60 (2004).
  • Kazama JJ, Gejyo F, Shigematsu T et al. Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism. Ther. Apher. Dial.9, 328–330 (2005).
  • Razzaque MS, St Arnaud R, Taguchi T et al. FGF-23, vitamin D and calcification: the unholy triad. Nephrol. Dial. Transplant.20, 2032–2035 (2005).
  • De Beur SM, Finnegan RB, Vassiliadis J et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J. Bone Miner. Res.17, 1102–1110 (2002).
  • Berndt TJ, Bielesz B, Craig TA et al. Secreted frizzled-related protein-4 reduces sodium-phosphate co-transporter abundance and activity in proximal tubule cells. Pflugers Arch.451, 579–587 (2006).
  • Clevers H. Wnt/β-catenin signaling in development and disease. Cell127, 469–480 (2006).
  • Baig-Lewis S, Peterson-Nedry W, Wehrli M. Wingless/Wnt signal transduction requires distinct initiation and amplification steps that both depend on Arrow/LRP. Dev. Biol.306, 94–111 (2007).
  • Fuerer C, Nusse R, Ten Berge D. Wnt signalling in development and disease. Max Delbruck Center for Molecular Medicine meeting on Wnt Signaling in Development and Disease. EMBO Rep.9, 134–138 (2008).
  • Yamamoto H, Komekado H, Kikuchi A. Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of β-catenin. Dev. Cell11, 213–223 (2006).
  • Rowe PS, Kumagai Y, Gutierrez G et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone34, 303–319 (2004).
  • Nampei A, Hashimoto J, Hayashida K et al. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J. Bone Miner. Metab.22, 176–184 (2004).
  • Dobbie H, Unwin RJ, Faria NJ et al. Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol. Dial. Transplant.23, 730–733 (2008).
  • Gowen LC, Petersen DN, Mansolf AL et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J. Biol. Chem.278, 1998–2007 (2003).
  • Liu S, Rowe PS, Vierthaler L et al. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J. Endocrinol.192, 261–267 (2007).
  • Bresler D, Bruder J, Mohnike K et al. Serum MEPE–ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J. Endocrinol.183, R1–R9 (2004).
  • Rowe PS, Garrett IR, Schwarz PM et al. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE–ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone36, 33–46 (2005).
  • Rowe PS, Matsumoto N, Jo OD et al. Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone39, 773–786 (2006).
  • Jain A, Fedarko NS, Collins MT et al. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J. Clin. Endocrinol. Metab.89, 4158–4161 (2004).
  • Martin A, David V, Laurence JS et al. Degradation of MEPE, DMP1 and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology149(4), 1757–1772 (2007).
  • Carpenter TO, Ellis BK, Insogna KL et al. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic ostemalacia-causing tumors. J. Clin. Endocrinol. Metab.90, 1012–1020 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.